The reporting of social determinants of health in pediatric dermatology clinical trials: a systematic review.

Autor:	Nwankwo C; University of Missouri- Kansas City School of Medicine, Kansas City, Missouri., Livinski AA; National Institutes of Health Library, Office of Research Services, National Institutes of Health, Bethesda, Maryland., Heath CR; Department of Dermatology, Temple University, Philadelphia, Pennsylvania., Castelo-Soccio L; Dermatology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
Jazyk:	angličtina
Zdroj:	International journal of women's dermatology [Int J Womens Dermatol] 2024 Aug 19; Vol. 10 (3), pp. e173. Date of Electronic Publication: 2024 Aug 19 (Print Publication: 2024).
DOI:	10.1097/JW9.0000000000000173
Abstrakt:	Background: Despite the acknowledgment of the importance of social determinants of health (SDOH) on clinical outcomes, few clinical trials provide information about SDOH. Including these markers in pediatric dermatologic clinical trials may lead to improved care and novel observations about the disease. Objective: Using a systematic review, assess the use of SDOH in pediatric dermatology clinical trials. Methods: CINAHL Plus, Cochrane: CENTRAL, Embase, PubMed, and Scopus were searched. English language randomized controlled trials about pediatric dermatology diseases published from January 2011 to May 2022 were included. Two authors independently screened all records using Covidence at 2 levels. Two authors independently collected data using Covidence and Microsoft Excel and assessed study quality. A protocol was registered at Open Science Framework: https://doi.org/10.17605/OSF.IO/B93VY. Results: A total of 6463 records were retrieved and 4298 were screened at title/abstract. Next, 1738 records were screened at full text and 1085 were included. Of these, 119 reported an SDOH factor for a pediatric dermatology disease. Income or socioeconomic status was the factor most reported followed by social support, location, and health insurance. Most of the studies were conducted outside of the United States. Limitations: There are a limited number of dermatology clinical trials that include a pediatric population. Conclusion: Despite including over 1000 pediatric dermatology clinical trials, only 119 used SDOH. Pediatric dermatology researchers must prioritize including and reporting additional SDOH in clinical trials if the goal is to impact and improve clinical care and innovate for diverse populations of patients. Competing Interests: None.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu